Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Allen Chung"'
Autor:
Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Publikováno v:
Thoracic Cancer, Vol 15, Iss 7, Pp 529-537 (2024)
Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutat
Externí odkaz:
https://doaj.org/article/f50013384c9245aabf156b8d88673574
Autor:
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of tyrosine kinase inhibitor (TKI) tre
Externí odkaz:
https://doaj.org/article/bce3fbab037c45f29c24a461f2f07a28
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Autor:
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR -mutant non-small-cell lung cancer. We
Externí odkaz:
https://doaj.org/article/cb59f58b72a54d5aa11a70e91bdabd7a
Autor:
Shu-Min Lin, Chung-Shu Lee, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, Ko-Wei Chang, Tse-Hung Huang, Tsung-Hsien Yang, Yi-Hsien Shiao, Fu-Tsai Chung, Chyi-Liang Chen, Cheng-Hsun Chiu
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 257-264 (2023)
Objectives: This study explored the outcomes and predictors of early viral clearance among patients with COVID-19. Methods: This study recruited consecutive patients from March 1, 2020 to July 31, 2021. Early viral clearance was defined as having a d
Externí odkaz:
https://doaj.org/article/44838a1c18134fcbaf38372d2ae476d1
Autor:
Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, Li-Chung Chiu, Chiung-Hsin Chang, Ping-Chi Liu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Yu-Ching Lin, Cheng-Ta Yang, How-Wen Ko
Publikováno v:
Vaccines, Vol 12, Iss 5, p 474 (2024)
Real-world clinical experience of using anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (SCLC) patients has rarely been report
Externí odkaz:
https://doaj.org/article/fbd6cda30b6c4cde94dd95d9edb830f2
Autor:
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe clinical outcomes of sequential treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs are unclear. Thus
Externí odkaz:
https://doaj.org/article/db4839ec0a994a6298da90412b223b41
Autor:
Shu-Min Lin, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, Ko-Wei Chang, Tse-Hung Huang, Tsung-Hsien Yang, Yi-Hsien Shiao, Chung-Shu Lee, Fu-Tsai Chung, Chyi-Liang Chen, Cheng-Hsun Chiu
Publikováno v:
Biomedical Journal, Vol 46, Iss 1, Pp 100-109 (2023)
Background: Reliable clinical and laboratory predictors of coronavirus disease 2019 (COVID-19) disease progression could help to identify the subset of patients who are susceptible to severe symptoms. This study sought to identify the predictors for
Externí odkaz:
https://doaj.org/article/b02eb6aed0bf4ab5b00b681e25fa85db
Autor:
Shu-Min Lin, Chih-Hsiang Chang, Ting-Yu Lin, Allen Chung-Cheng Huang, Chiung-Hung Lin, Yung-Chang Chen, Pao-Hsien Chu
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 3169-3176 (2022)
Cardiorenal syndrome type I (CRS I) is defined as the development of acute kidney injury (AKI) following acute decompensated heart failure (ADHF). The clinical significance of endothelial markers in ADHF-associated AKI has yet to be clarified. This s
Externí odkaz:
https://doaj.org/article/3011de611bd946eea9873b60464ed89c
Autor:
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) patients was lacking. 310 patients of advanced NSCLC with common EGFR mutati
Externí odkaz:
https://doaj.org/article/17eff21402b64752921f6d7b503a59e8
Autor:
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data c
Externí odkaz:
https://doaj.org/article/c4d2ac6158d7496993153c06a2d2085c